<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765815</url>
  </required_header>
  <id_info>
    <org_study_id>Exparel TKA</org_study_id>
    <nct_id>NCT02765815</nct_id>
  </id_info>
  <brief_title>A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients</brief_title>
  <official_title>A Prospective Randomized Case Series Comparison on the Clinical Efficacy of Exparel Local Anesthetic in Total Knee Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holy Cross Hospital, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holy Cross Hospital, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, single-blinded, randomized, case-control study. The
      study is conducted by a single investigator at an orthopedic surgery institute, with a
      minimum 6 week post operative follow-up period of TKA patients who receive Exparel compared
      with the surgeon's standard method (detailed below) for pain management intraoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, single-blinded, randomized, case-control study. The
      study is conducted by a single investigator at an orthopedic surgery institute, with a
      minimum 6 week post operative follow-up period. Subjects scheduled for a planned total knee
      arthroplasty procedure will be consented and those meeting study criteria will be randomized
      to receive intra-operative injections at the surgical site of liposomal bupivicaine plus a
      multi-drug cocktail, or a multi-drug cocktail alone.

      This study will recruit subjects on an ongoing basis with a minimum of 130 study participants
      and a maximum of 156. Efficacy data on surgical pain control and safety data will be
      collected at frequent intervals during the hospitalization. Each study participant will be
      followed for a minimum 6 week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    competing protocol
  </why_stopped>
  <start_date type="Anticipated">February 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient reported Visual Analog Scale (VAS) pain intensity score. Post-surgery hours 4-24.</measure>
    <time_frame>VAS pain intensity scores will be collected starting four hours after end of surgery and every 4 hours thereafter until hour 24.</time_frame>
    <description>The area under the curve (AUC) of the VAS scores from 4-24 hours will be compared between the two treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported VAS pain intensity score. Post-surgery hours 24-48.</measure>
    <time_frame>VAS pain intensity scores will be collected starting 24 hours after end of surgery and every 4 hours thereafter until hour 48, or discharge.</time_frame>
    <description>The AUC of the VAS scores from 24-48 hours or until discharge will be compared between the two treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported VAS pain intensity score. Post-surgery hours 48-72.</measure>
    <time_frame>VAS pain intensity scores will be collected starting 48 hours after end of surgery and every 4 hours thereafter until hour 72, or discharge.</time_frame>
    <description>The AUC of the VAS scores from 48-72 hours or until discharge will be compared between the two treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost:benefit analysis</measure>
    <time_frame>TKA hospitalization charges, and VAS pain intensity scores pre-operative on day of surgery, 2-week and 6-week followup visits.</time_frame>
    <description>Correlation between hospital charges and improvement in VAS pain intensity score from baseline to the 2-week and 6-week follow-up time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <arm_group>
    <arm_group_label>Exparel plus multi-drug cocktail</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-drug cocktail alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine, 266mg</intervention_name>
    <arm_group_label>Exparel plus multi-drug cocktail</arm_group_label>
    <other_name>Exparel Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.5 % with Epinephrine</intervention_name>
    <arm_group_label>Multi-drug cocktail alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac 30mg</intervention_name>
    <arm_group_label>Exparel plus multi-drug cocktail</arm_group_label>
    <arm_group_label>Multi-drug cocktail alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 10mg</intervention_name>
    <arm_group_label>Exparel plus multi-drug cocktail</arm_group_label>
    <arm_group_label>Multi-drug cocktail alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.25% with Epinephrine</intervention_name>
    <arm_group_label>Exparel plus multi-drug cocktail</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 88 years of age.

          2. Subject is scheduled to undergo primary unilateral Total Knee Arthroplasty.

          3. Subject willing and able to sign the informed consent.

          4. Subject is fluent in verbal and written English.

          5. Subject agrees to take Liposomal bupivacaine or standard of care equivalent.

        Exclusion Criteria:

          1. Previous Partial or Total Knee Arthroplasty of the study knee. Previous Non-Implant
             surgery on the study knee and contralateral knee is permitted.

          2. Subject is pregnant or planning to become pregnant while enrolled in the study.

          3. Subject has a history of narcotic or alcohol abuse.

          4. Subjects with hepatic disease or renal impairment (alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) &gt;2.5 x upper limit of normal or estimated glomerular
             filtration rate (eGFR) &lt; 30 ml/min within 30 days of surgery).

          5. For any reason, in the opinion of the investigator, the Subject may not be a suitable
             candidate for study participation (i.e., history of noncompliance, drug dependency,
             etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Roche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holy Cross Orthopedic Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Cross Hospital Orthopedic Research Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5.</citation>
    <PMID>17403800</PMID>
  </results_reference>
  <results_reference>
    <citation>Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d'Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology. 1999 Jul;91(1):8-15.</citation>
    <PMID>10422923</PMID>
  </results_reference>
  <results_reference>
    <citation>Fetherston CM, Ward S. Relationships between post operative pain management and short term functional mobility in total knee arthroplasty patients with a femoral nerve catheter: a preliminary study. J Orthop Surg Res. 2011 Feb 7;6:7. doi: 10.1186/1749-799X-6-7.</citation>
    <PMID>21294923</PMID>
  </results_reference>
  <results_reference>
    <citation>American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030.</citation>
    <PMID>22227789</PMID>
  </results_reference>
  <results_reference>
    <citation>Bagsby DT, Ireland PH, Meneghini RM. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty. 2014 Aug;29(8):1687-90. doi: 10.1016/j.arth.2014.03.034. Epub 2014 Apr 4.</citation>
    <PMID>24793570</PMID>
  </results_reference>
  <results_reference>
    <citation>Broome CB, Burnikel B. Novel strategies to improve early outcomes following total knee arthroplasty: a case control study of intra articular injection versus femoral nerve block. Int Orthop. 2014 Oct;38(10):2087-9. doi: 10.1007/s00264-014-2392-0. Epub 2014 Jun 18.</citation>
    <PMID>24938586</PMID>
  </results_reference>
  <results_reference>
    <citation>Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012 Oct;19(5):530-6. doi: 10.1016/j.knee.2011.12.004. Epub 2012 Jan 28.</citation>
    <PMID>22285545</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TKA</keyword>
  <keyword>Knee replacement</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

